Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Conditions: HCC Interventions: Drug: PD-1 monoclonal antibody and lenvatinib; Drug: PD-1 monoclonal antibody Sponsors: Chen Xiaoping Not yet recruiting

https://clinicaltrials.gov/study/NCT06311929

Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research